Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Alamar Biosciences

Request full access

Improving human health by developing innovative immunoassays and engineering picomolar affinity antibodies

Hayward, United StatesFounded 2018Biotech & Life Sciences

About Alamar Biosciences

Alamar BioSciences is a biotechnology startup that operates in the field of proteomics, the large-scale study of proteins. The company has developed a groundbreaking technology called NULISA™, which has the ability to detect and measure proteins in the human body with unprecedented sensitivity and range. This technology has the potential to revolutionize our understanding of the role of proteins in health and disease, and could significantly improve the early detection and treatment of various diseases.

Alamar's primary clients are researchers and clinicians who are interested in profiling and validating clinically relevant protein biomarkers. These biomarkers can be used to develop new diagnostic tests and treatments for a wide range of diseases. The company's business model is based on providing these clients with access to its NULISA™ technology and ARGO™ system, a fully automated, high-throughput precision proteomics platform.

The company generates revenue by charging for the use of its technology and platform. This includes fees for the detection and quantification of low-abundance proteins, as well as for the ability to focus on a single target or multiplex hundreds to thousands of targets in a single experiment. The company's technology also reduces the need for technical expertise, which could make it more attractive to potential clients.

In summary, Alamar BioSciences is a promising startup that is poised to make a significant impact in the field of proteomics. Its innovative technology could transform the way we understand and treat diseases, and its business model has the potential to generate substantial revenue.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2026
Outcome tier
Unicorn$1–10B valuation tier

Alamar Biosciences in the Hayward ecosystem

Live from Dealroom

The Alamar Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Alzheimer's Drug Discovery Foundation

Series A5 investors entered at this stage

  • Qiming Venture Partners
  • Sherpa Venture Partners
  • Samsara BioCapital
  • Illumina Ventures
  • Morningside Venture Partners

Series B and later4 investors entered at this stage

  • Illumina Ventures
  • Morningside Venture Partners
  • Sherpa Venture Partners
  • Samsara BioCapital
Team profiled 14 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
12 countries with
team presence
🇺🇸 United States88.9%
🇩🇪 Germany2.2%
🇬🇧 United Kingdom1.7%
🇨🇳 China1.7%
🇸🇪 Sweden1.1%
Top 5 of 12 shown
Web traffic by country
17K monthly visits
across markets
🇺🇸 United States63.5%
🇬🇧 United Kingdom8.2%
🇨🇦 Canada5.9%
🇮🇳 India5.3%
🇩🇪 Germany4.7%
Top 5 markets shown

Patents

Estimated portfolio value
$505k

5 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Alamar Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Alamar Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.